array(0) { }

For Researchers

This page has information on funding opportunities and research policies.

Receive research competitions updates by subscribing to our researcher email list.

Learn about results from previous competitions.

funding opportunities

2025 CLINICIAN-SCIENTIST EMERGING LEADER AWARD

Registration Deadline: April 24, 2025, 5 p.m. EST – Download Registration of Interest Form.
Full Application Deadline: June 5, 2025, 5 p.m. EST – Download Application Form.

More details about the competition and application process can be found in the Competition Guide.

Applicants can apply for funding at two levels, up to $20,000 or up to $40,000 over two years, dependent on the amount of protected research time they have.

If you have questions or have trouble submitting please contact us at research@fightingblindness.ca


Past Funding Opportunities

2024 EARLY CAREER RESEARCH GRANT COMPETITION

 THIS COMPETITION IS NOW COMPLETE. LEARN ABOUT THE COMPETITION RESULTS.

More details about the competition and application process can be found in the Competition Guide PDF | WORD.

The 2024 Research Grant competition will support exceptional early career researchers with interest in retinal (including optic nerve) degeneration.

The program is open to early career principal investigators from Canadian institutions with a budget of up to $200,000 over two years per award.

Applications from across the spectrum of retinal research are welcome, including but not limited to discovery, translational, clinical and epidemiological research.

The competition is open to all research related to retinal degeneration but may prioritize funding projects with potential to impact individuals with inherited retinal diseases (e.g. retinitis pigmentosa, Usher syndrome, choroideremia), age-related macular degeneration, diabetic retinopathy or glaucoma.

If you have questions or have trouble submitting, please contact us at research@fightingblindness.ca

Competition and application process can be found in the Competition Guide.

FBC Policies & Positions

Created and Implemented September 17, 2014

Fighting Blindness Canada (FBC) has implemented a patent rights policy for FBC-funded research. The policy can be downloaded here: PDF

Created March 22, 2010

Stem cell research holds promise for finding treatments for various retinal dystrophies. Fighting Blindness Canada (FBC) is committed to finding treatments for retinal dystrophies and supports stem cell research as per the Assisted Human Reproduction Act (AHRA), which became law in Canada in March 2004. The Act and its framework ensure the consistent and regulated conduct of research, which balances respect for human life and potential for modern science. FBC acknowledges the highly sensitive and ethical issues addressed by the Act concerning embryonic stem cell research, and supports efforts to identify alternative sources for therapeutic applications. FBC respects all points of view on this important topic.

For details about Assisted Human Reproduction in Canada visit www.ahrc-pac.gc.ca.

If you wish not to support embryonic stem cell research, your donation to FBC can be directed to alternative sources for therapeutic applications, such as gene therapy or to education and public awareness.

Created May 2007

Fighting Blindness Canada (FBC) does not provide funds for indirect costs associated with research. While FBC recognizes that these are indeed legitimate expenditures, we believe the funding of such costs is the responsibility of governments and/or research institutions – not donors.

Fighting Blindness Canada is a member in good standing of the Health Charities Coalition of Canada (HCCC). All HCCC members abide by this funding policy. See the HCCC position statement on indirect costs.

Join the Fight!

Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.

I have read and accepted the privacy policy